



Belviq XR® (lorcaserin) – New Formulation Approval

- On July 19, 2016, [Eisai announced the FDA approval of Belviq XR \(lorcaserin\)](#) extended-release oral tablets, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes).
 - The safety and efficacy of coadministration with other products for weight loss have not been established.
 - The effect of Belviq XR on cardiovascular morbidity and mortality has not been established.
- Lorcaserin is also available as [Belviq](#), an oral 10 mg tablet.
- The approval of Belviq XR was based on clinical data that confirmed bioequivalence of once daily 20 mg tablets with twice daily 10 mg tablets.
- The recommended dose of Belviq XR is one tablet (20 mg) orally once daily. The dose of Belviq is one tablet (10 mg) orally twice daily.
 - Discontinue if 5% weight loss is not achieved by week 12.
- Eisai plans to launch Belviq XR in the fall of 2016. Belviq XR will be available as 20 mg extended-release tablets.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.